Axsome Therapeutics (NASDAQ:AXSM) & Kite Pharma (KITE) Head-To-Head Analysis

Axsome Therapeutics (NASDAQ: AXSM) and Kite Pharma (NASDAQ:KITE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares Axsome Therapeutics and Kite Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics N/A -127.58% -73.83%
Kite Pharma -1,092.54% -59.15% -48.12%

Insider & Institutional Ownership

27.1% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 87.7% of Kite Pharma shares are held by institutional investors. 35.2% of Axsome Therapeutics shares are held by company insiders. Comparatively, 14.0% of Kite Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Axsome Therapeutics and Kite Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics 0 0 4 0 3.00
Kite Pharma 0 10 7 0 2.41

Axsome Therapeutics currently has a consensus price target of $19.50, indicating a potential upside of 297.96%. Kite Pharma has a consensus price target of $93.20, indicating a potential downside of 48.22%. Given Axsome Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Kite Pharma.

Valuation & Earnings

This table compares Axsome Therapeutics and Kite Pharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics N/A N/A -$27.20 million ($1.36) -3.60
Kite Pharma N/A N/A N/A ($6.90) -26.09

Kite Pharma is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Axsome Therapeutics beats Kite Pharma on 5 of the 9 factors compared between the two stocks.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Kite Pharma Company Profile

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply